BridgeBio Pharma (BBIO) has soared 145% in the past year, hitting a record high of $75.10. Valued at $13.8 billion, BBIO focuses on genetic disease treatments with products like BBP-265 and BBP-831 in the pipeline. Revenue expected to grow 123% this year, 79.63% next year, but earnings may dip 61.11% before rising 44.41%.

BBIO’s technical indicators show a 100% “Buy” opinion with a Weighted Alpha of +168.02. The stock recently traded at $70.96, maintaining a Trend Seeker “Buy” signal. Wall Street analysts have mostly positive views, with price targets between $66 and $110. Short interest is high at 12.3% of the float.

Despite analyst optimism, caution is advised due to high short interest. Value Line rates BBIO “Above Average,” while CFRA’s MarketScope Advisor rates it a “Sell.” Morningstar sees fair value at $74.24. 54 Motley Fool investors are bullish, 29 are not, and Seeking Alpha rates it a “Buy.”

Read more at Yahoo Finance: This Hot Biotech Stock Just Set New All-Time Highs